Kediclave 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg and Clavulanic Acid 125 mg. Amoxycillin is a broad-spectrum penicillin-class antibiotic that inhibits bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic Acid is a beta-lactamase inhibitor that prevents enzymatic degradation of Amoxycillin by beta-lactamase-producing bacteria, thereby extending its antibacterial spectrum. This synergistic combination is effective against a wide range of Gram-positive and Gram-negative pathogens, including strains resistant to Amoxycillin alone. Kediclave 625 is indicated for the treatment of various infections such as respiratory tract infections (including sinusitis, bronchitis, and pneumonia), urinary tract infections, skin and soft tissue infections, otitis media, and dental infections. The dosage and duration of therapy should be determined by a healthcare professional based on the severity and type of infection, as well as patient-specific factors. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and vomiting, while hypersensitivity reactions are rare but possible. Caution is advised in patients with a history of penicillin allergy or hepatic impairment. Kediclave 625 Tablet should be used under medical supervision to ensure appropriate use and to minimize the risk of antibiotic resistance.